[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://www.lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 72, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 82734, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 65, "title": "Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1021376, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 750442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 63, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary K. Lee Ph.D.", "age": 47, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark A. Meltz J.D.", "age": 50, "title": "General Counsel & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Tomlin", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 33.41, "open": 33.8, "dayLow": 32.75, "dayHigh": 35.155, "regularMarketPreviousClose": 33.41, "regularMarketOpen": 33.8, "regularMarketDayLow": 32.75, "regularMarketDayHigh": 35.155, "payoutRatio": 0.0, "beta": -0.11, "forwardPE": -41.02381, "volume": 64639, "regularMarketVolume": 64639, "averageVolume": 49414, "averageVolume10days": 68070, "averageDailyVolume10Day": 68070, "bid": 33.83, "ask": 34.78, "bidSize": 1, "askSize": 1, "marketCap": 732066624, "fiftyTwoWeekLow": 7.65, "fiftyTwoWeekHigh": 35.155, "allTimeHigh": 396.8, "allTimeLow": 7.65, "priceToSalesTrailing12Months": 17855.283, "fiftyDayAverage": 19.435, "twoHundredDayAverage": 12.8394, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 455840768, "profitMargins": 0.0, "floatShares": 12170981, "sharesOutstanding": 21243954, "sharesShort": 161792, "sharesShortPriorMonth": 166193, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.0076, "heldPercentInsiders": 0.27677, "heldPercentInstitutions": 0.50164, "shortRatio": 4.83, "shortPercentOfFloat": 0.0092, "impliedSharesOutstanding": 21243954, "bookValue": 17.058, "priceToBook": 2.0201664, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -325660000, "trailingEps": -22.75, "forwardEps": -0.84, "lastSplitFactor": "1:20", "lastSplitDate": 1748822400, "enterpriseToRevenue": 11118.067, "enterpriseToEbitda": -2.472, "52WeekChange": 1.4932835, "SandP52WeekChange": 0.13613915, "quoteType": "EQUITY", "currentPrice": 34.46, "targetHighPrice": 45.0, "targetLowPrice": 12.0, "targetMeanPrice": 29.66667, "targetMedianPrice": 32.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 319624000, "totalCashPerShare": 15.064, "ebitda": -184380992, "totalDebt": 44285000, "quickRatio": 10.026, "currentRatio": 10.296, "totalRevenue": 41000, "debtToEquity": 13.456, "revenuePerShare": 0.003, "returnOnAssets": -0.24162, "returnOnEquity": -0.75751, "grossProfits": 41000, "freeCashflow": -79681128, "operatingCashflow": -165015008, "revenueGrowth": -0.559, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -2483.5332, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 3.14277, "regularMarketPrice": 34.46, "corporateActions": [], "postMarketTime": 1765578890, "regularMarketTime": 1765573202, "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623936600000, "postMarketChangePercent": -1.944278, "postMarketPrice": 33.79, "postMarketChange": -0.66999817, "regularMarketChange": 1.05, "regularMarketDayRange": "32.75 - 35.155", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 49414, "fiftyTwoWeekLowChange": 26.81, "fiftyTwoWeekLowChangePercent": 3.504575, "fiftyTwoWeekRange": "7.65 - 35.155", "fiftyTwoWeekHighChange": -0.6949997, "fiftyTwoWeekHighChangePercent": -0.019769583, "fiftyTwoWeekChangePercent": 149.32835, "earningsTimestamp": 1762981200, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -22.75, "epsForward": -0.84, "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "marketState": "CLOSED", "fiftyDayAverageChange": 15.025, "fiftyDayAverageChangePercent": 0.77308977, "twoHundredDayAverageChange": 21.620598, "twoHundredDayAverageChangePercent": 1.6839259, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2025-12-13"}]